Tyrosine kinase inhibitorFDA-approvedSecond-line
Abemaciclib
How it works
Blocks the CDK4/6 enzymes that drive cell division in cancer cells, allowing the body's natural repair mechanisms to take over.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
Studies have shown that abemaciclib can improve progression-free survival and overall survival in patients with hormone receptor-positive breast cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Abemaciclib with Chemotherapy for Advanced Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Testing Combination of Anti-cancer Drugs for Rare Cancers | Breast Cancer | phase-1 | — | Source → |
| Testing New Treatments for Advanced Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Breast Cancer Treatment Study | Breast Cancer | preclinical | — | Source → |
| Testing Chemotherapy vs Hormone Therapy with Abemaciclib in Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Abemaciclib Fails to Meet Primary Endpoint in Brain Metastases Study | Lung Cancer | phase-2 | A volumetric decrease in target intracranial lesions was 22.7% for NSCLC and 18.8% for melanoma cohorts. | Source → |
| Combining Ferulic Acid with Breast Cancer Drugs May Improve Treatment | Breast Cancer | lab-study | — | Source → |
| Abemaciclib May Cause Skin Reactions in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| New Combination Therapy Tested for Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.